SCHEMBL26930982

SCHEMBL26930982

COC(=O)c1c(Nc2ccc(F)c(F)c2CCCNC(=O)OC(C)(C)C)ccc(C(F)(F)F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ POLB P06746 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ CA1 P00915 4/20 0.33
▸ CA2 P00918 4/20 0.33
▸ CA12 O43570 3/20 0.33
▸ CA9 Q16790 3/20 0.33
▸ EPHX2 P34913 2/20 0.33
▸ KDR P35968 1/20 0.33
▸ ACVR1B P36896 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ ACVRL1 P37023 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ DRD2 P14416 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26930971 0.86 PDE3B (0.37) PDE3BPDE3APOLBLMNAGAA
SCHEMBL31438977 0.84 ACVR1B (0.34) PDE3BPDE3APOLBGAATDP1
SCHEMBL30660386 0.81 ACVR1B (0.38) PDE3BPDE3ACA1CA2CA12
SCHEMBL26944617 0.81 ACVR1B (0.38) PDE3BPDE3ACA1CA2CA12
SCHEMBL26930973 0.80 ACVR1B (0.38) LMNAGAAACVR1BTGFBR1ACVRL1
SCHEMBL31439077 0.79 ATR (0.41) PDE3BPDE3APOLBGAACA1
SCHEMBL26931239 0.79 TAS2R14 (0.43) ACVR1BTGFBR1ACVRL1
SCHEMBL26931044 0.76 ACVR1B (0.39) CA1CA2CA12CA9KDR
SCHEMBL30032633 0.74 LMNA (0.46) PDE3BPDE3APOLBLMNAKDM4E
SCHEMBL30660385 0.74 CA1 (0.44) POLBGAATDP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-12-04 — — US disclosed
EP-4536660-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2025-04-16 — — EP disclosed
CN-119325476-A Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2025-01-17 — — CN disclosed
WO-2023238065-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN5A PDE3B 383/4885PDE3A 376/4885POLB 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback